Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up
By J. Sousa, Marco A. Costa, Alexandre Abizaid, B. Rensing, A. Abizaid, L. Tanajura, K. Kozuma, Glenn Van Langenhove, A. Sousa, R. Falotico and 3 more. Circulation, 2001
754 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging, Surgery
View Paper: https://www.semanticscholar.org/paper/4d925be62d01510957e6945939a3234989f60f3d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Surgery
Citations in the corpus
- Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin-E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) Registry (2004, background): “The primary outcome was the occurrence of major adverse cardiac events, defined as (1) death, (2) nonfatal myocardial infarction, or (3) target vessel revascularization.”
- mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. (2002, background): “…drug that is currently used to block immune rejec-New York, New York 10021 tion of transplanted organs (Saunders et al., 2001) and in trials for the treatment of cancer (Dudkin et al., 2001; Hidalgo and Rowinsky, 2000) and for the prevention of restenosis after angioplasty (Sousa et al., 2001).”